Defects in mitochondrial dynamics and mitochondrial DNA instability

Mitochondrial Disorders Caused by Nuclear Genes

Volumn 9781461437222, Issue , 2013, Pages 141-161

  Yu Wai Man, Patrick ^a,c   Lenaers, Guy ^b   Chinnery, Patrick F ^a,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Montpellier University Medical Center   (France)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Autosomal dominant optic atrophy; Charcot Marie Tooth disease; DRP1; GDAP1; MFN1; MFN2; Mitochondrial disorders; Mitochondrial DNA deletion; Mitochondrial dynamics; OPA1; OPA3; Optic atrophy; Retinal ganglion cell

Indexed keywords

EID: 84926258109     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3722-2_9     Document Type: Chapter

References (110)

1. Holt IJ, Harding AE, Morganhughes JA (1988) Deletions of muscle mitochondrial-DNA in patients with mitochondrial myopathies. Nature 331:717-719
2. Wallace DC, Singh G, Lott MT et al (1988) Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 242:1427-1430
3. DiMauro S, Schon EA (2003) Mechanisms of disease: mitochondrial respiratory-chain diseases. N Engl J Med 348:2656-2668
4. Taylor RW, Turnbull DM (2005) Mitochondrial DNA mutations in human disease. Nat Rev Genet 6:389-402
5. McFarland R, Taylor RW, Turnbull DM (2010) A neurological perspective on mitochondrial disease. Lancet Neurol 9:829-840
6. Van Goethem G, Dermaut B, Lofgren A, Martin JJ, Van Broeckhoven C (2001) Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 28:211-212
7. Spelbrink JN, Li FY, Tiranti V et al (2001) Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene LF-like protein localized in mitochondria. Nat Genet 28:223-231
8. Chinnery PF, Zeviani M (2008) 155th ENMC workshop: polymerase gamma and disorders of mitochondrial DNA synthesis, 21-23 September 2007, Naarden, The Netherlands. Neuromuscul Disord 18:259-267
9. Krishnan KJ, Reeve AK, Samuels DC et al (2008) What causes mitochondrial DNA deletions in human cells? Nat Genet 40:275-279
10. Khrapko K (2011) The timing of mitochondrial DNA mutations in aging. Nat Genet 43:726- 727
11. Bristow EA, Griffiths PG, Andrews RM, Johnson MA, Turnbull DM (2002) The distribution of mitochondrial activity in relation to optic nerve structure. Arch Ophthalmol 120:791-796
12. Westermann B (2010) Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol 11:872-884
13. Barron MJ, Griffiths P, Turnbull DM, Bates D, Nichols P (2004) The distributions of mitochondria and sodium channels reflect the specific energy requirements and conduction properties of the human optic nerve head. Br J Ophthalmol 88:286-290
14. Chan DC (2006) Mitochondrial fusion and fission in mammals. Annu Rev Cell Dev Biol 22:79-99
15. Campello S, Scorrano L (2010) Mitochondrial shape changes: orchestrating cell pathophysiology. EMBO Rep 11:678-684
16. Praefcke GJK, McMahon HT (2004) The dynamin superfamily: universal membrane tubulation and fission molecules? Nat Rev Mol Cell Biol 5:133-147
17. Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E (2008) Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci 9:505-518
18. Chen H, ChanDC(2009) Mitochondrial dynamics-fusion, fission, movement, and mitophagyin neurodegenerative diseases. Hum Mol Genet 18:R169-R176
19. Yu-Wai-Man P, Griffiths PG, Chinnery PF (2011) Mitochondrial optic neuropathies-disease mechanisms and therapeutic strategies. Prog Retin Eye Res 30(2):81-114
20. Huizing M, Brooks BP, AniksterY (2005) Optic atrophies in metabolic disorders. Mol Genet Metab 86:51-60
21. Yu-Wai-Man P, Griffiths PG, Burke A et al (2010) The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmol 117:1538-1546
22. Cohn AC, Toomes C, Potter C et al (2007) Autosomal dominant optic atrophy: penetrance and expressivity in patients with OPA1 mutations. Amer J Ophthalmol 143:656-662
23. CohnAC, Toomes C, HewittAWet al (2008) The natural history of OPA1-related autosomal dominant optic atrophy. Br J Ophthalmol 24:24
24. Votruba M, Fitzke FW, Holder GE, Carter A, Bhattacharya SS, MooreAT (1998) Clinical features in affected individuals from 21 pedigrees with dominant optic atrophy. Arch Ophthalmol 116:351-358
25. Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF (2009) Inherited mitochondrial optic neuropathies. J Med Genet 46:145-158
26. La Morgia C, Ross-Cisneros FN, SadunAA et al (2010) Melanopsin retinal ganglion cells are resistant to neurodegeneration in mitochondrial optic neuropathies. Brain 133:2426-2438
27. Davies V, Votruba M (2006) Focus on molecules: the OPA1 protein. Exp Eye Res 83:1003- 1004
28. Olichon A, Elachouri G, Baricault L, Delettre C, Belenguer P, Lenaers G (2007) OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis. Cell Death Diff 14:682-692
29. Akepati VR (2008) Characterization of OPA1 isoforms isolated from mouse tissues. J Neurochem 106:372-383
30. Lenaers G, Reynier P, Elachouri G et al (2009) OPA1 functions in mitochondria and dysfunctions in optic nerve. Int J Biochem Cell Biol 41:1866-1874
31. Alexander C, Votruba M, Pesch UEA et al (2000) OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet 26:211-215
32. Delettre C, Lenaers G, Griffoin JM et al (2000) Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 26:207-210
33. Ferre M, Amati-Bonneau P, Tourmen Y, Malthiery Y, Reynier P (2005) eOPA1: an online database for OPA1 mutations. Hum Mutat 25:423-428
34. Ferre M, Bonneau D, Milea D et al (2009) Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations. Hum Mutat 30:E692- 705
35. Fuhrmann N, Alavi MV, Bitoun P et al (2009) Genomic rearrangements in OPA1 are frequent in patients with autosomal dominant optic atrophy. J Med Genet 46:136-144
36. Almind GJ, Gronskov K, Milea D, Larsen M, Brondum-Nielsen K, Ek J (2011) Genomic deletions in OPA1 in Danish patients with autosomal dominant optic atrophy. BMC Med Genet 12:49
37. Schimpf S, Fuhrmann N, Schaich S, Wissinger B (2008) Comprehensive cDNA study and quantitative transcript analysis of mutant OPA1 transcripts containing premature termination codons. Hum Mutat 29:106-112
38. Amati-Bonneau P, Odent S, Derrien C et al (2003) The association of autosomal dominant optic atrophy and moderate deafness may be due to the R445H mutation in the OPA1 gene. Am J Ophthalmol 136:1170-1171
39. Amati-Bonneau P, Guichet A, OlichonA et al (2005) OPA1 R445H mutation in optic atrophy associated with sensorineural deafness. Ann Neurol 58:958-963
40. Li CM, Kosmorsky G, Zhang K, Katz BJ, Ge J, Traboulsi EI (2005) Optic atrophy and sensorineural hearing loss in a family caused by an R445H OPA1 mutation.Am J Med Genet Part A 138A:208-211
41. Payne M, Yang ZL, Katz BJ et al (2004) Dominant optic atrophy, sensorineural hearing loss, ptosis, and ophthalmoplegia: a syndrome caused by a missense mutation in OPA1. Am J Ophthalmol 138:749-755
42. Hudson G, Amati-Bonneau P, Blakely EL et al (2008) Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain 131:329-337
43. Amati-Bonneau P, Valentino ML, Reynier P et al (2008)OPA1 mutations induce mitochondrial DNA instability and optic atrophy plus phenotypes. Brain 131:338-351
44. Spinazzi M, Cazzola S, Bortolozzi M et al (2008) A novel deletion in the GTPase domain of OPA1 causes defects in mitochondrial morphology and distribution, but not in function. Hum Mol Genet 17:3291-3302
45. Yu-Wai-Man P, Griffiths PG, Gorman GS et al (2010) Multi-system neurological disease is common in patients with OPA1 mutations. Brain 133:771-786
46. Marchbank NJ, Craig JE, Leek JP et al (2002) Deletion of the OPA1 gene in a dominant optic atrophy family: evidence that haploinsufficiency is the cause of disease. J Med Genet 39:e47
47. Aijaz S, Erskine L, Jeffery G, Bhattacharya SS, VotrubaM(2004) Developmental expression profile of the optic atrophy gene product: OPA1 is not localized exclusively in the mammalian retinal ganglion cell layer. Invest Ophthalmol Visual Sci 45:1667-1673
48. Bette S, Schlaszus H, Wissinger B, Meyermann R, Mittelbronn M (2005) OPA1, associated with autosomal dominant optic atrophy, is widely expressed in the human brain. Acta Neuropathol 109:393-399
49. Wang AG, Fann MJ, Yu HY, Yen MY (2006) OPA1 expression in the human retina and optic nerve. Exp Eye Res 83:1171-1178
50. Pellegrini L, Scorrano L (2007) A cut short to death: Parl and Opa1 in the regulation of mitochondrial morphology and apoptosis. Cell Death Diff 14:1275-1284
51. Martinelli P, Rugarli EI (2010) Emerging roles of mitochondrial proteases in neurodegeneration. Biochim Biophys Acta 1797
52. Rugarli EI, Langer T (2006) Translating m-AAA protease function in mitochondria to hereditary spastic paraplegia. Trends Mol Med 12:262-269
53. Casari G, De Fusco M, Ciarmatori S et al (1998) Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell 93:973-983
54. Chevrollier A (2008) Hereditary optic neuropathies share a common mitochondrial coupling defect. Ann Neurol 63:794-798
55. Zanna C, Ghelli A, PorcelliAM et al (2008) OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain 131:352-367
56. Song ZY, Chen H, Fiket M, Alexander C, Chan DC (2007) OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, andYme1L. J Cell Biol 178:749-755
57. Cipolat S, Rudka T, Hartmann D et al (2006) Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling. Cell 126:163-175
58. Frezza C, Cipolat S, de Brito OM et al (2006) OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 126:177-189
59. Suen DF, Norris KL, Youle RJ (2008) Mitochondrial dynamics and apoptosis. Genes Dev 22:1577-1590
60. Lodi R, Tonon C, Valentino ML et al (2004) Deficit of in vivo mitochondrialATP production in OPA1-related dominant optic atrophy. Ann Neurol 56:719-723
61. Yu-Wai-Man P, Trenell MI, Hollingsworth KG, Griffiths PG, Chinnery PF (2011) OPA1 mutations impair mitochondrial function in both pure and complicated dominant optic atrophy. Brain 134:e164
62. Lodi R, Tonon C, Valentino ML et al (2011) Defective mitochondrial adenosine triphosphate production in skeletal muscle from patients with dominant optic atrophy due to OPA1 mutations. Arch Neurol 68:67-73
63. Yu-Wai-Man P, Sitarz KS, Samuels DC et al (2010) OPA1 mutations cause cytochrome c oxidase deficiency due to loss of wild-typemtDNAmolecules. HumMol Genet 19:3043-3052
64. Capps GJ, Samuels DC, Chinnery PF (2003)A model of the nuclear control of mitochondrial DNA replication. J Theor Biol 221:565-583
65. Chinnery PF, Samuels DC (1999) Relaxed replication of mtDNA: a model with implications for the expression of disease. Am J Hum Genet 64:1158-1165
66. Durham SE, Samuels DC, Cree LM, Chinnery PF (2007) Normal levels of wild-type mitochondrial DNA maintain cytochrome c oxidase activity for two pathogenic mitochondrial DNA mutations but not for m.3243A→G. Am J Hum Genet 81:189-195
67. Davies VJ, Hollins AJ, Piechota MJ et al (2007) Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum Mol Genet 16:1307-1318
68. Alavi MV, Bette S, Schimpf S et al (2007) A splice site mutation in the murine Opa1 gene features pathology of autosomal dominant optic atrophy. Brain 130:1029-1042
69. Williams PA, Morgan JE, Votruba M (2011) Opa1 deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion cell dendropathy. Brain 133:2942-2951
70. Yu-Wai-Man P, Davies VJ, Piechota MJ, Cree LM, Votruba M, Chinnery PF (2009) Secondary mtDNA defects do not cause optic nerve dysfunction in a mouse model of dominant optic atrophy. Invest Ophthalmol Vis Sci 50:4561-4566
71. Anikster Y, Kleta R, Shaag A, Gahl WA, Elpeleg O (2001) Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. Am J Hum Genet 69:1218-1224
72. Reynier P, Amati-Bonneau P, Verny C et al (2004) OPA3 gene mutations responsible for autosomal dominant optic atrophy and cataract. J Med Genet 41(9):e110
73. Da Cruz S, Xenarios I, Langridge J, Vilbois F, Parone PA, Martinou JC (2003) Proteomic analysis of the mouse liver mitochondrial inner membrane. J Biol Chem 278:41566-41571
74. Huizing M, Dorward H, Ly L et al (2010) OPA3, mutated in 3-methylglutaconic aciduria type III, encodes two transcripts targeted primarily to mitochondria. Mol Genet Metab 100:149- 154
75. Ryu SW, Jeong HJ, Choi M, Karbowski M, Choi C (2010) Optic atrophy 3 as a protein of the mitochondrial outer membrane induces mitochondrial fragmentation. Cell Mol Life Sci 67:2839-2850
76. Pei WH, Kratz LE, Bernardini I et al (2010) A model of Costeff syndrome reveals metabolic and protective functions of mitochondrial OPA3. Dev 137:2587-2596
77. Davies VJ, Powell KA, White KE et al (2008) A missense mutation in the murine Opa3 gene models human Costeff syndrome. Brain 131:368-380
78. Friedman JR, Lackner LL, West M, DiBenedetto JR, Nunnari J, Voeltz GK (2011) ER tubules mark sites of mitochondrial division. Science 334:358-362
79. Waterham HR, Koster J, van RoermundCWT, Mooyer PAW, Wanders RJA, Leonard JV (2007) A lethal defect of mitochondrial and peroxisomal fission. N Engl J Med 356:1736-1741
80. Chang CR, Manlandro CM, Arnoult D et al (2010) A lethal de novo mutation in the middle domain of the dynamin-relatedGTPase Drp1 impairs higher order assembly and mitochondrial division. J Biol Chem 285:32494-32503
81. Pareyson D, Marchesi C (2009) Diagnosis, natural history, and management of Charcot- Marie-Tooth disease. Lancet Neurol 8:654-667
82. Zuchner S, Vance JM (2006) Mechanisms of disease: a molecular genetic update on hereditary axonal neuropathies. Nat Clin Pract Neurol 2:45-53
83. Amati-Bonneau P, Milea D, Bonneau D et al (2009) OPA1-associated disorders: phenotypes and pathophysiology. Int J Biochem Cell Biol 41:1855-1865
84. Zuchner S, Mersiyanova IV, Muglia M et al (2004) Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 36:449-451
85. Zuchner S, De Jonghe P, Jordanova A et al (2006) Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol 59:276-281
86. Cartoni R, Martinou JC (2009) Role of mitofusin 2 mutations in the physiopathology of Charcot-Marie-Tooth disease type 2A. Exp Neurol 218:268-273
87. Chen HC, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC (2003) Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 160:189-200
88. Detmer SA, Velde CV, Cleveland DW, Chan DC (2008) Hindlimb gait defects due to motor axon loss and reduced distal muscles in a transgenic mouse model of Charcot-Marie-Tooth type 2A. Hum Mol Genet 17:367-375
89. Chen H, McCaffery JM, Chan DC (2007) Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 130:548-562
90. Guillet V, Gueguen N, Cartoni R et al (2011) Bioenergetic defect associated with mKATP channel opening in a mouse model carrying a mitofusin 2 mutation. Faseb J 25:1618-1627
91. Detmer SA, Chan DC (2007) Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations. J Cell Biol 176:405-414
92. Loiseau D, Chevrollier A, Verny C et al (2007) Mitochondrial coupling defect in Charcot- Marie-Tooth type 2A disease. Ann Neurol 61:315-323
93. Del Bo R, Moggio M, Rango M et al (2008) Mutated mitofusin 2 presents with intrafamilial variability and brain mitochondrial dysfunction. Neurology 71:1959-1966
94. Pich S, Bach D, Briones P et al (2005) The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system. Hum Mol Genet 14:1405-1415
95. Chen HC, Vermulst M, Wang YE et al (2010) Mitochondrial fusion is Rrquired for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell 141:280-289
96. Rouzier C, Bannwarth S, Chaussenot A et al (2012) The MFN2 gene is responsible for mitochondrial DNA instability and optic atrophy 'plus' phenotype. Brain 135:23-34
97. Yu-Wai-Man P, Chinnery PF (2012) Dysfunctional mitochondrial maintenance: what breaks the circle of life? Brain 135:9-11
98. Sitarz KS, Yu-Wai-Man P, Pyle A, Stewart JD, Rautenstrauss B, Seeman P, Reilly MM, Horvath R, Chinnery PF (2012) MFN2 mutations cause compensatory mitochondrial DNA proliferation. Brain. Epub ahead of print. PMID:22492563
99. Baxter RV, Ben Othmane K, Rochelle JM et al (2002) Ganglioside-induced differentiationassociated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet 30:21-22
100. Claramunt R, Pedrola L, Sevilla T et al (2005) Genetics of Charcot-Marie-Tooth disease type 4A: mutations, inheritance, phenotypic variability, and founder effect. J Med Genet 42:358-365
101. Zimon M, Baets J, FabriziGMet al (2011) Dominant GDAP1 mutations cause predominantly mild CMT phenotypes. Neurology 77:540-548
102. Niemann A, Wagner KM, Ruegg M, Suter U (2009) GDAP1 mutations differ in their effects on mitochondrial dynamics and apoptosis depending on the mode of inheritance. Neurobiol Dis 36:509-520
103. Pedrola L, Espert A, Wu X, Claramunt R, Shy ME, Palau F (2005) GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria. Hum Mol Genet 14:1087-1094
104. Niemann A, Ruegg M, La PadulaV, Schenone A, Suter U (2005) Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J Cell Biol 170:1067-1078
105. Cassereau J, Chevrollier A, Gueguen N et al (2009) Mitochondrial complex I deficiency in GDAP1-related autosomal dominant Charcot-Marie-Tooth disease (CMT2K). Neurogenetics 10:145-150
106. Payne BA, Wilson IJ, Hateley CA et al (2011) Mitochondrial aging is accelerated by antiretroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet 43:806-810
107. Cao LQ, Shitara H, HoriiT et al (2007) The mitochondrial bottleneck occurs without reduction of mtDNA content in female mouse germ cells. Nat Genet 39:386-390
108. Cree LM, Samuels DC, Lopes S et al (2008) A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat Genet 40:249-254
109. Khrapko K (2008) Two ways to make an mtDNA bottleneck. Nat Genet 40:134-135
110. Elachouri G, Vidoni S, Zanna C et al (2011) OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution. Genome Res 21:12-20.